ArticleNPJ breast cancer2017
Dramatic response of metaplastic breast cancer to chemo-immunotherapy.
Article in NPJ breast cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04549584 (Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer), which is not on this map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
Who cites it
45 citing papers in PubMed.
- Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.Nature communications · 2022Trial
- A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma.Scientific reports · 2020Trial
- A retrospective study of metaplastic breast cancer: Treatment and prognosis through chemotherapy followed by radiotherapy.Medicine · 2026Article
- Long-Term Response to Pembrolizumab in Metastatic Metaplastic Breast Carcinoma: A Case Report.The American journal of case reports · 2026Article
- The Correlation Between PD-L1 Expression in Metaplastic Breast Cancer and Clinical-Pathological Features and Prognosis.Medicina (Kaunas, Lithuania) · 2026Article
- Spindle Cell (Metaplastic) Carcinoma of the Breast Showing No Clinical Benefit with Pembrolizumab-Based Neoadjuvant Chemoimmunotherapy.Surgical case reports · 2026Article
- Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer.NPJ breast cancer · 2025Article
- Neoadjuvant Versus Adjuvant Therapy for Metaplastic Breast Cancer: Insights from the National Cancer Database-Is There a Winning Strategy?Annals of surgical oncology · 2025Article
- Survival outcomes after systemic treatment of high-grade triple-negative metaplastic breast cancer versus triple-negative breast cancer of no special type.Virchows Archiv : an international journal of pathology · 2025Article
- Triple-Negative Metaplastic Breast Cancer Ameliorated Following KEYNOTE-522: A Case Report.Cureus · 2025Article
- Clinical Implication of Subcategorizing T2 Category in Metaplastic Breast Cancer.Journal of breast cancer · 2025Article
- Clinicopathological characteristics, treatments and oncological outcomes in metaplastic breast cancer: a Brazilian multicenter analysis.Frontiers in oncology · 2025Article
- Chemotherapy as a critical treatment modality for non-surgical metaplastic breast cancer: evidence from SEER database and clinical cohort.Frontiers in oncology · 2025Article
- NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.Nature communications · 2024Article
- A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report.Thoracic cancer · 2024Article
- Primary Squamous Carcinoma: A Description of a Rare Histological Type of Breast Cancer.Cureus · 2024Article
- Case report: Successful treatment of a rare HER2-positive advanced breast squamous cell carcinoma.Frontiers in pharmacology · 2024Article
- The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.Breast cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.